Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trialJames O. Lindsay, John A. Snowden, Daniel Hind et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 19
Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn’s disease: the ASTIClite RCTJames O. Lindsay, John A. Snowden, Daniel Hind et al.|Efficacy and Mechanism Evaluation|2024Cited by 1
Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker resultsClaire Roddie, Ruth J. Pepper, Josefina Cortés-Hernández et al.|Blood|2025Cited by 0